Dactolisib (hydrochloride)

Dactolisib (hydrochloride)

• CAS Number: 2319647-83-9
• UNSPSC Description: Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR with IC50 of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2[1].
• Target Antigen: Autophagy; mTOR; PI3K
• Type: Reference compound
• Related Pathways: Autophagy;PI3K/Akt/mTOR
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/dactolisib-hydrochloride.html
• Smiles: CN(C1=O)C2=C(C3=CC(C4=CC5=C(N=C4)C=CC=C5)=CC=C3N=C2)N1C6=CC=C(C=C6)C(C)(C#N)C.Cl
• Molecular Weight: 506.00
• References & Citations: [1]Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863.|[2]Roper J, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One, 2011, 6(9), e25132.|[3]Lee M, et al. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015 Jul 15;21(14):3204-15.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported